In the above Highlights [Highlights (2012) J Pharmacol Exp Ther 343:539] and the HTML Table of Contents, there are several errors. In the heading, Selesipag should be Selexipag. Lines 3 and 6 should be PGI2 and not PGI2. Lines 19 and 20 should be EP3 receptor antagonist and not EP3 receptor antagonist.
The online versions have been corrected.
The printer regrets this error and apologizes for any inconvenience it may have caused.
- Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics